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 Kidney injury molecule-1 / T-cell immu-
noglobulin and mucin domain-containing 
protein-1 (KIM-1 / TIM-1 in humans, 
Kim-1 / Tim-1 in rodents) is a type 1 mem-
brane receptor 1,2 that is the most highly 
upregulated protein in the proximal tubule 
of the injured kidney ( Figure 1 ). It has also, 
to varying degrees, been reported to 
be expressed on immune cells. 2,3 In the kid-
ney, Kim-1 is upregulated in a wide variety 
of human diseases and in various animal 
models. 1 A large amount of KIM-1 protein 
is also shed into the urine, making it a use-
ful urinary biomarker for kidney injury. 1 
Kim-1 functions as a phosphatidylserine 
receptor that recognizes and internalizes 
apoptotic cells. 4 Kim-1 also functions as a 
scavenger receptor, mediating the uptake 
of modifi ed low-density lipoprotein and 
necrotic-cell debris. 4 Kim-1 expression 
transforms proximal tubular epithelial cells 
into semi professional phagocytes. In the 
immune system, Kim-1 / Tim-1 has been 
implicated in activation of T-helper 2 (Th 2), 
Th 1, and Th 17 diff erentiation. 2 It has also 
been proposed to be an activating receptor 
in B cells, dendritic cells, and natural killer 
T cells. 2,3,5,6 Many of the experiments that 
have led to these conclusions have relied on 
antibodies against Kim-1 / Tim-1, which 
have been presumed to be agonists or 
antagonists, or Kim-1 / Tim-1-Fc fusion 
proteins as key reagents. 2 
 Nozaki and colleagues 7 (this issue) report 
that a low-avidity anti-Tim-1 antibody, 
RMT1-10, used as an antagonist of Kim-1 / 
Tim-1, suppressed T-cell immune responses 
and glomerular / tubulointerstitial changes 
in a model of disease induced by anti-
glomerular basement membrane globulin. 
(Th is antibody may not be identical to the 
commercially available antibody with the 
same name. 8 ) Treatment with RMT1-10 
reduced crescentic glomerulonephritis and 
Th 1 / Th 17 cellular responses both in sys-
temic immune cells and within the kidney 
while increasing renal Foxp3   +   cell and 
interleukin-10 mRNA, characteristics of 
regulatory T cells and Th 2 cells, respectively. 
Two other studies have recently demon-
strated a partial protection of kidneys by the 
same RMT1-10 antibody in acute kidney 
injury induced by cisplatin or ischemia – 
reperfusion. 9,10 Th e authors of these studies 
also concluded that Kim-1 / Tim-1 mediated 
activation of detrimental T-cell and / or 
innate immune responses. 9,10 Activation 
of injurious Th1 cells was inhibited or 
Th 1-related cytokines were diminished by 
RMT1-10. In the study by Nozaki and col-
leagues, 7 however, a signifi cant portion of 
the injected RMT1-10 antibody was shown 
to accumulate at proximal tubules where 
Kim-1 is expressed. Given the very high 
expression of Kim-1 / Tim-1 in the kidney 
relative to its expression in immune cells, 
care must be taken in interpreting the results 
achieved with the antibody ( Figure 1 ). 
 Questions have also been raised concern-
ing the RMT1-10 antibody. RMT1-10 was 
shown to stimulate (not antagonize) Tim-1 
on regulatory B cells, a newly identifi ed 
population whose function in kidney injury 
is not clear. 6 In addition, RMT1-10 has 
been reported to be an antagonist of Th 1 /
 Th17 activation and also induced Th2 
cytokine expression, 2 indicating that the 
mechanism by which RMT1-10 affects 
T-cell activation is not well defi ned. Con-
versely, 3B3 antibody stimulates Th 1 activa-
tion, even though it binds to the same 
domain of Tim-1 as RMT1-10. 2 Recently, 
with the use of Tim-1 knockout and trans-
genic mice, it was reported that RMT1-4 is 
the only commercially available Tim-1-spe-
cifi c monoclonal antibody (RMT1-10 was 
not mentioned). 5 Th ese studies suggest that 
the current model for the role of Tim-1 
in T-cell activation may require revision, 
and the antibody approach requires better 
defi nition of the mechanism of action. 
 Several recent fi ndings have suggested 
that the widely held notion that Tim-1 is a 
Th 2 regulator requires reconsideration. 2 In 
studies using Kim-1 / Tim-1 knockout mice, 
Tim-1 expression was very low (or nonex-
istent) in activated T cells or Th 2 cells. 2,5 
Additionally, the Tim-1 knockout study 
demonstrated that Tim-1 may weakly con-
tribute to infl ammatory lung injury but not 
to Th 2-cell activation. 2,5 Transgenic expres-
sion of Tim-1 in T cells did not stimulate 
Th 2 diff erentiation. 2,5 Rather, Tim-1 expres-
sion was proposed to be present in subsets 
of activated B cells, dendritic cells, and 
invariant natural killer T cells, 2,3,5 each of 
which have been implicated in the patho-
physiology of kidney injury ( Figure 1 ). 11 
Th e potential function of Tim-1 in renal 
dendritic cells has not been well character-
ized. 3 To test the specifi city of Tim-1 func-
tion in T cells,  Rag-1  – / –  mice were used to 
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evaluate T-cell function in cisplatin-induced 
and ischemia-induced kidney injury. 9,10 
However, these mice lack both T and B cells. 
Splenocytes (which contain both T and B 
cells) were used for the adoptive transfer in 
the ischemia study. 10 Th erefore, cells other 
than T cells might be contributing to the 
observed eff ects in  Rag-1  – / –  mice. 
 Following kidney injury, numerous proxi-
mal tubules become KIM-1 positive, and 
copious amounts (nanogram levels) of solu-
ble KIM-1 protein are shed into extracellular 
spaces, including the urine. 1,4,7 In contrast, 
few T cells are present in the injured 
kidney, 7,9,10 and a very small proportion of 
the activated T cells have been proposed to 
be Kim-1 / Tim-1 positive. 7 For instance, in 
the report by Nozaki and colleagues, 7 Kim-1 / 
Tim-1-positive T cells account for only 2 % 
of all activated CD4   +   cells, and very few 
interstitial CD4   +   T cells (1.3 per high-power 
fi eld) are found in the glomerulonephritis 
kidney model. Additionally, immunostain-
ing of Kim-1 in rodent acute kidney injury 
showed an absence of interstitial Kim-1, 
suggesting that Kim-1 / Tim-1 expression is 
predominantly restricted to the tubules. 4 
Consequently, there is a dramatic imbalance 
between nominal Tim-1 expression on a 
minority of T cells and abundant kidney 
tubular Kim-1 expression. Th e abundant 
amount of tubule and soluble Kim-1 / Tim-1 
may potentially sequester administered 
anti-Kim-1 / Tim-1 blocking antibodies, as 
evident in binding of the injected RMT1-10 
antibody to the apical side of tubules in the 
glomerulonephritis model ( Figure 1 ). 7 Th us, 
inhibitory antibodies may not be the most 
efficient means of manipulating Kim-
1 / Tim-1 function on immune cells in the 
setting of tubular injury, and T cells may not 
express very much Kim-1 / Tim-1. 
 Th us, there remain many caveats in inter-
preting data from studies using antibodies 
against Kim-1 / Tim-1. Antibody blocking 
experiments will require a standardized anti-
body with well-characterized functional 
properties and high specifi city to Kim-1 / Tim-
1. In addition, Kim-1 / Tim-1 cell-type-specifi c 
knockout or transgenic mice, such as CD3-
derived T cell- or B cell-specifi c transgenic 
mice and Kim-1 / Tim-1 knockout mice, 5 can 
be used to assess the role of Kim-1 / Tim-1 in 
immune cells during kidney injury. Cells iso-
lated from Tim-1 knockout or transgenic 
mice can also increase the specifi city of adop-
tive transfer experiments. It is likely that Kim-
1 / Tim-1 ’ s phagocytosis / endocytosis function 
is crucial in tubular injury and repair. Th ere-
fore, phagocytosis-specifi c functional knock-
out (mutant) mice and / or Kim-1-specifi c 
conditional knockout or transgenic mice 
should be used to evaluate Kim-1 ’ s function 
in the proximal tubule and the immune sys-
tem. Even though obstacles remain, studies 
such as those of Nozaki  et al. 7 using reagents 
that interfere with or activate Kim-1 / Tim-1 
should give us important insights into disease 
mechanisms and potentially lead to specifi c 
Kim-1 / Tim-1 targeted therapies in humans. 
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 Figure 1  |  Kim-1 / Tim-1 is expressed in injured proximal tubule epithelium and shed but 
may also be expressed in activated lymphocytes and / or myeloid cells in injured kidney. 
Tubular Kim-1 / Tim-1 promotes clearance of apoptotic and necrotic cells but may also contribute 
to uptake of oxidized lipids if its expression is prolonged. A large amount of Kim-1 / Tim-1 is shed to 
extracellular spaces. It has been proposed that Kim-1 / Tim-1 may also be expressed, albeit at much 
lower levels, by activated lymphocytes and / or myeloid cells in injury-induced immune response. 
Antibodies can activate cells or prevent ligand binding to Kim-1/Tim-1.  They also may interact with 
shed Kim-1/Tim-1. LDL, low-density lipoprotein. 
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 Can we cure HIV-1-associated 
nephropathy in transgenic mice ? 
 Patricio E.  Ray 1 , 2 
 HIV-1 – associated nephropathy (HIVAN) is a rapidly progressive form 
of focal segmental glomerulosclerosis. HIV transgenic mice can 
develop a HIVAN-like renal disease. Zhong  et al. show that the oral 
administration of a cyclic nucleotide phosphodiesterase 4 inhibitor 
and a retinoic acid receptor-  agonist can prevent the development 
of HIVAN in transgenic mice, acting through a cAMP-dependent 
mechanism that is independent of HIV-1 genes. These findings suggest 
that endogenous host factors play a critical role in HIVAN. 
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different from that of AIDS-associated 
Kaposi ’ s sarcoma, HIVAN is characterized 
by the excessive proliferation of renal 
glomerular and tubular epithelial cells, 
leading to the microcystic transformation 
of renal tubules and rapid development of 
focal segmental glomerulo sclerosis. Th ere-
fore, the new study by Zhong  et al. 1 (this 
issue) challenges us to ask a similar type of 
question: Can we cure HIVAN in trans-
genic (Tg) mice without attacking the 
HIV-1 genes? 
 Briefl y, the study by Zhong  et al. 1 shows 
that the oral administration of two drugs 
that increase the intracellular levels of 
cyclic adenosine monophosphate (cAMP), 
rofl umilast and Am580, is capable of cur-
ing HIVAN in Tg mice without aff ecting 
the expression of HIV-1 genes. Rofl umi-
last is a cyclic nucleotide phosphodieste-
rase 4 (PDE4) inhibitor that increases 
the intracellular concentration of cAMP 
by blocking its degradation. Am580 is a 
specifi c retinoic acid receptor-  (RAR  ) 
agonist that has several systemic and renal 
effects, including increasing the intra-
cellular levels of cAMP. Both drugs, acting 
in a synergistic manner, prevented the 
progression of the renal disease in HIV-Tg 
mice by blocking the dediff erentiation and 
proliferation of podocytes through a 
cAMP / protein kinase A / CREB-dependent 
pathway 1 ( Figure 1 ). Th is pathway requires 
the participation of RAR  in the nucleus 
of podocytes, in addition to the direct acti-
vation of cAMP and protein kinase A in 
the cytoplasm of these cells. Th e mecha-
nism by which retinoic acid receptor ago-
nists induce a direct activation of cAMP 
in the cytoplasm is not well understood, 
but similar findings have been docu-
mented in acute myeloblastic leukemia 
cells. 1 However, Am580 did not prevent 
the progression of HIVAN in dual HIV-
Tg / RAR  knockout mice, 2 suggesting that 
the nuclear RAR  plays a key role in this 
process. Th us, more studies are needed to 
determine how RAR  may induce the 
rapid activation of cAMP in the cyto-
plasm, and to validate this pathway in 
normal human podocytes. Finally, Zhong 
 et al. 1 conclude that the benefi cial eff ects 
of rofl umilast and Am580 were independ-
ent of HIV viral genes. Overall, these 
provocative fi ndings raise several interest-
ing issues that need to be discussed. 
 First, Zhong  et al. 1 used a new colony of 
HIV-Tg mice that was re-derived from the 
parent HIV-Tg 26 mouse line. Th erefore, to 
understand how HIVAN can be cured in 
these mice, it is necessary to review the 
natural history of renal disease in Tg 26 
mice. Briefl y, these mice carry a replication-
defi cient   gag / pol PNL4-3 HIV proviral 
genomic DNA driven by the endogenous 
HIV-1 promoter. 3,4 Th e mRNA expression 
of HIV-1 is detected in a wide range of cells, 
including glomerular and tubular epithelial 
cells. 3 – 5 Viral proteins cannot, however, be 
detected in the circulation or peripheral 
blood mono nuclear cells. Heterozygous 
mice are born with normal kidneys but 
develop progressive renal disease during 
their fi rst months of life. 3,4 Usually, male 
mice develop a more rapid and progressive 
renal disease when compared with female 
mice. 3 – 5 Severe edema and nephrotic 
syndrome occur approximately between 
60 and 250 days of age. 3 – 5 Tg 26 mice 
